ArticleCureus2025
Late-Onset Immune-Mediated Hepatotoxicity Induced by the Immune Checkpoint Inhibitor Pembrolizumab in Lung Cancer: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Immune Checkpoint Inhibitor-induced Hepatitis, an Emerging Issue in Precision Cancer Therapy Era: A Narrative Literature Review.Rambam Maimonides medical journal · 2026Review
- Successful management of severe hepatotoxicity induced by combined chemotherapy and immune checkpoint inhibitor: a case report.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer (LC) remains the leading cause of cancer-related death worldwide. The introduction of immune checkpoint inhibitors, such as pembrolizumab, has improved survival in selected patients. However, these therapies may cause immune-mediated adverse events, including hepatotoxicity, which poses a diagnostic challenge due to its low incidence and nonspecific presentation. We report a case of a patient with LC who developed persistent elevation of liver enzymes after 17 cycles of pembrolizumab, with no infectious or metabolic abnormalities, consistent with immune-mediated drug-induced liver injury. This case underscores the importance of continuous liver function monitoring throughout immunotherapy, even after long-term exposure, to enable early recognition and management of delayed immune-related hepatotoxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.